Geoffrey I. Shapiro

Brigham and Women's Hospital

Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

h-index116
i10-index391
Publications2,054
Citations57,969

Grants

49 total · 18 active

NIH #1R01CA307291-01

Macrophage-directed strategies for BRCA-associated breast cancer

Active
Amount
$772K
Period
2026-04-10 → 2031-03-31
PIs
3
Est. capacity / PI
~4 students

NIH #2P50CA168504-11

Project 4: Combined targeting of DNA repair and macrophage-mediated immunosuppression in BRCA1/2-associated breast cancer

Active
Amount
$347K
Period
2013-09-17 → 2030-07-31
PIs
1
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA269021-03

Pathology Core

Active
Amount
$411K
Period
2024-05-01 → 2029-04-30
PIs
1
Est. capacity / PI
~3 students

Awarded at DANA-FARBER CANCER INST

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

49 total · 18 active

NIH #1R01CA307291-01

Macrophage-directed strategies for BRCA-associated breast cancer

Active
Amount
$772K
Period
2026-04-10 → 2031-03-31
PIs
3
Est. capacity / PI
~4 students

NIH #2P50CA168504-11

Project 4: Combined targeting of DNA repair and macrophage-mediated immunosuppression in BRCA1/2-associated breast cancer

Active
Amount
$347K
Period
2013-09-17 → 2030-07-31
PIs
1
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA269021-03

Pathology Core

Active
Amount
$411K
Period
2024-05-01 → 2029-04-30
PIs
1
Est. capacity / PI
~3 students

Awarded at DANA-FARBER CANCER INST

NIH #5P01CA269021-02

Pathology Core

Active
Amount
$591K
Period
2024-05-01 → 2029-04-30
PIs
1
Est. capacity / PI
~5 students

Awarded at DANA-FARBER CANCER INST

NIH #1P01CA269021-01A1

Pathology Core

Active
Amount
$431K
Period
2024-05-01 → 2029-04-30
PIs
1
Est. capacity / PI
~4 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA285308-03

Genetically engineered mouse model to improve therapy of NUT carcinoma

Active
Amount
$657K
Period
2023-09-19 → 2028-08-31
PIs
3
Est. capacity / PI
~1 students

NIH #5R01CA285308-02

Genetically engineered mouse model to improve therapy of NUT carcinoma

Active
Amount
$629K
Period
2023-09-19 → 2028-08-31
PIs
3
Est. capacity / PI
~1 students

NIH #1R01CA285308-01

Genetically engineered mouse model to improve therapy of NUT carcinoma

Active
Amount
$672K
Period
2023-09-19 → 2028-08-31
PIs
3
Est. capacity / PI
~1 students

NIH #4R01CA272982-04

Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers

Active
Amount
$796K
Period
2022-09-01 → 2027-08-31
PIs
1
Est. capacity / PI
~3 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA272982-02

Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers

Active
Amount
$389K
Period
2022-09-01 → 2027-08-31
PIs
1
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #1R01CA272982-01

Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers

Active
Amount
$415K
Period
2022-09-01 → 2027-08-31
PIs
1
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #3UM1CA186709-09S1

DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN

Active
Amount
$194K
Period
2014-03-13 → 2027-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5UM1CA186709-09

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Active
Amount
$2.1M
Period
2014-03-13 → 2027-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P30CA006516-61

Program 12: Developmental Therapeutics

Active
Amount
$48K
Period
1997-03-10 → 2026-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P30CA006516-60

Program 12: Developmental Therapeutics

Active
Amount
$47K
Period
1997-03-10 → 2026-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P30CA006516-59

Program 12: Developmental Therapeutics

Active
Amount
$41K
Period
1997-03-10 → 2026-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P30CA006516-58

Program 12: Developmental Therapeutics

Active
Amount
$42K
Period
1997-03-10 → 2026-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #2P30CA006516-57

Program 12: Developmental Therapeutics

Active
Amount
$42K
Period
1997-03-10 → 2026-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5UM1CA186709-08

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Amount
$2.0M
Period
2014-03-13 → 2026-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #4UM1CA186709-07

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Amount
$2.6M
Period
2014-03-13 → 2026-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA272982-03

Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers

Amount
$378K
Period
2022-09-01 → 2025-08-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA240243-05

ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)

Amount
$394K
Period
2020-08-03 → 2025-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA240243-04

ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)

Amount
$353K
Period
2020-08-03 → 2025-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA240243-03

ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)

Amount
$377K
Period
2020-08-03 → 2025-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA240243-02

ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)

Amount
$355K
Period
2020-08-03 → 2025-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #1P50CA240243-01A1

ATR inhibitor-mediated reversal of PARP inhibitor resistance in high-grade serous ovarian cancer (HGSOS)

Amount
$413K
Period
2020-08-03 → 2025-07-31
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA168504-10

Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer

Amount
$2.3M
Period
2013-09-17 → 2025-05-31
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA168504-09

Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer

Amount
$2.2M
Period
2013-09-17 → 2024-05-31
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA168504-08

Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer

Amount
$2.3M
Period
2013-09-17 → 2024-05-31
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #3UM1CA186709-06S1

Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center

Amount
$100K
Period
2014-03-13 → 2023-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #2UM1CA186709-06

Dana‐Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)

Amount
$6.9M
Period
2014-03-13 → 2023-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #3UM1CA186709-06S2

XPO1 inhibitors Selinexor and Eltanexor in Combination with Venetoclax and Decitabine (ASTX727) in AML

Amount
$125K
Period
2021-03-01 → 2022-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P30CA006516-56

Program 12: Developmental Therapeutics

Amount
$93K
Period
1997-03-10 → 2021-11-30
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5UM1CA186709-05

Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis

Amount
$2.3M
Period
2014-03-13 → 2020-02-29
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5UM1CA186709-04

Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis

Amount
$2.0M
Period
2014-03-13 → 2020-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5UM1CA186709-03

Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis

Amount
$1.8M
Period
2014-03-13 → 2020-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #3UM1CA186709-03S1

Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis

Amount
$713K
Period
2014-03-13 → 2020-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5UM1CA186709-02

Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis

Amount
$1.5M
Period
2014-03-13 → 2019-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #1UM1CA186709-01

Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis

Amount
$1.4M
Period
2014-03-13 → 2019-02-28
PIs
3
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA090687-13

Cyclin-Dependent Kinase Inhibition During S Phase

Amount
$297K
Period
2001-04-01 → 2019-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #3R01CA090687-13S1

Cyclin-Dependent Kinase Inhibition During S Phase

Amount
$82K
Period
2001-04-01 → 2018-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #3R01CA090687-12S1

Cyclin-Dependent Kinase Inhibition During S Phase

Amount
$52K
Period
2001-04-01 → 2015-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA090687-12

Cyclin-Dependent Kinase Inhibition During S Phase

Amount
$288K
Period
2001-04-01 → 2015-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA090687-11

Cyclin-Dependent Kinase Inhibition During S Phase

Amount
$306K
Period
2001-04-01 → 2015-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5R01CA090687-10

Cyclin-Dependent Kinase Inhibition During S Phase

Amount
$306K
Period
2001-04-01 → 2015-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #2R01CA090687-09A1

Cyclin-Dependent Kinase Inhibition During S Phase

Amount
$332K
Period
2001-04-01 → 2015-02-28
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #3P30CA006516-55S4

Program 12: Developmental Therapeutics

Amount
$3K
Period
— → —
PIs
1
Est. capacity / PI
~0 students

Awarded at DANA-FARBER CANCER INST

NIH #5P30CA006516-55

Program 12: Developmental Therapeutics

Amount
$93K
Period
— → —
PIs
1
Est. capacity / PI
~1 students

Awarded at DANA-FARBER CANCER INST

NIH #5P50CA090578-07

Translational studies of Hsp90 inhibitors in NSCLC

Amount
$195K
Period
2003-09-19 → —
PIs
1
Est. capacity / PI
~3 students

Awarded at DANA-FARBER CANCER INST

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 366
Open author page on OpenAlex →